{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:41:30Z","timestamp":1793446890225,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijantimicag.2020.106107","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T02:37:12Z","timestamp":1595644632000},"page":"106107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Current trends in the real-life use of dalbavancin: report of a study panel"],"prefix":"10.1016","volume":"56","author":[{"given":"Emanuele","family":"Durante-Mangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita Dora","family":"Iula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Francesco","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano Franco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-8451","authenticated-orcid":false,"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106107_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0003","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","article-title":"Dalbavancin: a new lipoglycopeptide antibiotic","volume":"65","author":"Bailey","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0004","series-title":"Surveillance of antimicrobial resistance in Europe 2018","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1469-0691.2010.03214.x","article-title":"Management of multidrug-resistant enterococcal infections","volume":"16","author":"Arias","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0006","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020.http:\/\/www.eucast.org\/[accessed 19 December 2019]."},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","article-title":"Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin","volume":"82","author":"Jones","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0008","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019.http:\/\/www.eucast.org[accessed 13 July 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0009","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0010","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0012","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","volume":"4","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0013","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/TCRM.S86330","article-title":"Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)","volume":"12","author":"Leuthner","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1542\/peds.55.2.213","article-title":"Clindamycin treatment of osteomyelitis and septic arthritis in children","volume":"55","author":"Feigin","year":"1975","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0016","first-page":"276","article-title":"Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report","volume":"32","author":"\u00c1lvarez Otero","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in Gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jac5.1085","article-title":"Evaluation of dalbavancin on length of stay in acute bacterial skin and skin structure infections","volume":"2","author":"Jones","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0019","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.00020-07","article-title":"Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits","volume":"51","author":"Solon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0020","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0022","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple Weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1302\/2058-5241.2.160062","article-title":"Spondylodiscitis revisited","volume":"2","author":"Mavrogenis","year":"2017","journal-title":"EFORT Open Rev"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1308\/rcsann.2015.0009","article-title":"Management of adult spontaneous spondylodiscitis and its rising incidence","volume":"97","author":"Sur","year":"2015","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0026","doi-asserted-by":"crossref","first-page":"e82665","DOI":"10.1371\/journal.pone.0082665","article-title":"Infective endocarditis epidemiology over five decades: a systematic review","volume":"8","author":"Slipczuk","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0027","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/jac\/dkz006","article-title":"Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres","volume":"74","author":"Sader","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0028","first-page":"6:ofy028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijid.2018.07.016","article-title":"Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user","volume":"76","author":"Jones","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0032","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study","volume":"32","author":"Buz\u00f3n Mart\u00edn","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0033","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s15010-009-8269-2","article-title":"Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults","volume":"37","author":"Esposito","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0034","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections\u00a0: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0036","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0037","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1128\/AAC.00825-16","article-title":"Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs","volume":"60","author":"Karanika","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0038","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/ciw217","article-title":"Executive summary: Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0039","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.10.021","article-title":"The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis","volume":"26","author":"Onorato","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0041","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/cid\/ciy550","article-title":"Antimicrobial stewardship and intensive care unit mortality: a systematic review","volume":"68","author":"Lindsay","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0042","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmi.2019.08.017","article-title":"Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational working group","volume":"26","author":"Schweitzer","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0044","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","article-title":"Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis","volume":"16","author":"Schuts","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0045","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0046","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0047","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis","volume":"24","author":"Agarwal","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106107_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:12Z","timestamp":1760377032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0924857920302909"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106107","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current trends in the real-life use of dalbavancin: report of a study panel","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106107"}}